IPO Year: 2006
Exchange: NASDAQ
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f
Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated liver fibrosis in the PRC expected by early 2025 Cash and cash equivalents totaled $16.1 million as of June 30, 2024 SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs f
Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025 U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025 Acquired the rights to complementary assets relating to nintedanib through Gyre Pharmaceuticals to improve competitiveness in the PRC Cash and cash equivalents totaled $29.8 million as of March 31, 2024 SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic thera
Data readout from Phase 3 clinical trial in the People's Republic of China ("PRC") evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreement with GNI Cash and cash equivalents totaled $33.5 million as of December 31, 2023 SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre") (NASDAQ:GYRE), a cli
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
S-3 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
RW - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
RW - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company's Board of Directors and as a member of its Audit Committee. "Rodney has an extensive background in finance, accounting, and financial reporting with nearly four decades of experience working at global auditing and consulting firms," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies. We look forwa
EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that the last patient in Gyre Pharmaceuticals' pivotal Phase 3 trial in the People's Republic of China ("PRC") evaluating F351 (hydronidone) for Chronic Hepatitis B ("CHB")-associated liver fibrosis has completed the 52-week study. Gyre Pharmaceuticals expects to report topline data from this trial by the first quarter of 2025. "The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our developm
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the 8th Annual H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT). The live webcast will be available on the Events and Presentations page of Gyre's website. A webcast replay will be accessible following the live session. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San D
SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 8:30 AM ET (5:30 AM PT). The live webcast will be available on the Events and Presentations page of Gyre's website. A webcast replay will be accessible following the live session. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headqua
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 14-15, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. Presentation Schedule*All Times EDTWednesday, August 14, 2024 (Day 1)8:30-9:00*****Alta Global Group (MMA)Mobile-health Network (MNDR)9:15-9:45Steakholder Foods Ltd. (STKH)*****Regenx Tech (RGXTF)10:00-10:30*****Genius Group (GNS)*****10:45-11:15ARC Document Solutions (ARC)Xtract One Technologies (XTRA.TO)C
Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated liver fibrosis in the PRC expected by early 2025 Cash and cash equivalents totaled $16.1 million as of June 30, 2024 SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs f
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the Sidoti August Virtual Investor Conference on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT). To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on the Events and Presentations page of Gyre's website. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical co
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that China's National Medical Products Administration ("NMPA") has approved Gyre Pharmaceuticals' (Gyre's indirectly controlled subsidiary) avatrombopag maleate tablets for the treatment of thrombocytopenia ("TP") associated with chronic liver disease ("CLD") in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases. "The
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the publication of the manuscript titled "Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway" in the Journal of Gastroenterology and Hepatology. This publication includes both in vivo and in vitro studies supporting the potential of hydronidone (F351), a novel derivate of pirfenidone, as a promising therapy for the treatment of liver fibrosis. "Preclinical anim
Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that the Center for Drug Evaluation ("CDE") of China's National Medical Products Administration ("NMPA") has approved Gyre Pharmaceuticals' (Gyre's indirectly controlled subsidiary) Investigational New Drug ("IND") application for F230 tablets, a selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension ("PAH"). F230 was originally licensed from Eisai through Gyre's indirect majority stockholder, GNI Group Ltd.
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results. Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from Benzinga Pro. Bank of Montreal shares declined 7.1% to $89.32 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark O
U.S. stocks were lower, with the Dow Jones index falling more than 300 points on Wednesday. Shares of HEICO Corporation (NYSE:HEI) rose sharply during Wednesday's session following a second-quarter earnings beat. Heico posted quarterly GAAP earnings of 88 cents per share, beating market estimates of 81 cents per share. The company's quarterly sales came in at $955.395 million versus expectations of $951.206 million, according to data from Benzinga Pro. HEICO shares gained 4.6% to $221.76 on Wednesday. Here are some other big stocks recording gains in today's session. AST SpaceMobile, Inc. (NASDAQ:ASTS) shares gained 29% to $6.88 after the company announced a partnership with
Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEase reported fiscal first-quarter 2024 revenue growth of 7.2% year-on-year to $3.72 billion (26.9 billion Chinese yuan), missing the analyst consensus estimate of $3.79 billion. The Chinese gaming player’s adjusted EPADS of $1.81 beat the analyst consensus estimate of $1.79, according to data from Benzinga Pro. NetEase shares declined 4% to $91.02 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Akanda Corp. (NASDAQ:AKAN) shares climbed 101% to $4.81. The international medical cannabis company implemented
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share. This is unchanged from the same period last year. The company reported $27.17 million in sales this quarter. This is a 8.99 percent increase over sales of $24.93 million the same period last year.
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ:RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NA